Cidara Therapeutics, Inc.
CDTX
Rank in Stocks
#3183
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Share Price
$221.38
Last synced: 2026-01-08
Market Cap
$5.61B
Change (1 day)
0.00%
Change (1 year)
118.07%
Country
US
Trade Cidara Therapeutics, Inc. (CDTX)
Category
Healthcare
P/E ratio for Cidara Therapeutics, Inc. (CDTX)
P/E ratio as of October 2026 TTM: -46.61
According to Cidara Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -46.61. At the end of 2023 the company had a P/E ratio of -3.03.
P/E ratio history for Cidara Therapeutics, Inc. from 2012 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -46.61 | 4,514.49% |
| 2024 | -1.01 | -66.80% |
| 2023 | -3.03 | 92.37% |
| 2022 | -1.57 | 0.36% |
| 2021 | -1.57 | 36.53% |
| 2020 | -1.15 | -58.95% |
| 2019 | -2.80 | 171.57% |
| 2018 | -1.03 | -51.76% |
| 2017 | -2.14 | -31.74% |
| 2016 | -3.13 | -57.38% |
| 2015 | -7.34 | 565.49% |
| 2014 | -1.10 | -71.38% |
| 2013 | -3.85 | -46.17% |
| 2012 | -7.16 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -161.76% |
US
|
|
| -28.36 | -39.15% |
US
|
|
| -24.57 | -47.29% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -165.08% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.